[CAS NO. 55321-99-8]??T-1105
PRODUCTS SPECIFICATIONS [55321-99-8]
DESCRIPTION [55321-99-8]
Overview
| MDL | MFCD00233977 |
|---|---|
| Molecular Weight | 139.11 |
| Molecular Formula | C5H5N3O2 |
| SMILES | O=C(C1=NC=CN=C1O)N |
1 Publications Citing Use of MCE
Summary
T-1105, a structural analogue of T-705, is a novel broad-spectrum viral polymerase inhibitor. T-1105 inhibits the polymerases of RNA viruses after being converted to ribonucleoside triphosphate (RTP) metabolite. T-1105 has antiviral activity against various RNA viruses. T-1105 can be formed by nicotinamide mononucleotide adenylyltransferase [1] [2] .
IC50 & Target
In Vitro
T-1105 has antiviral activity against various RNA viruses, including Zika virus (ZIKV), influenza virus, arenaviruses, bunyaviruses, West Nile virus (WNV), yellow fever virus (YFV), and foot-and-mouth disease virus (FMDV)
[1]
[2]
.
T-1105 has good anti-RNA virus activity with values
EC
50
of 17 μM and 24 μM for parainfluenza-3 virus and Punta Toro virus in MDCK cells
[3]
.
T-1105 is a potential inhibitor of Zika virus replication
[4]
.
T-1105 can inhibit the SFTSV replication with an value
IC
50
of 49 μM in Vero cells and is not affect cell viability in 0-3 μM
[5]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Cytotoxicity Assay [4]
| Cell Line: | Vero cells |
| Concentration: | 1-4 μM |
| Incubation Time: | 72 h |
| Result: | Had potential antiviral activity against ZIKV strain SZ01 with an value EC 50 of 97.5 μM in Vero cells. |
Cell Viability Assay [5]
| Cell Line: | Vero cells |
| Concentration: | 0-3 μM |
| Incubation Time: | 4 h |
| Result: | Did not affect cell viability in the test range (0-3 μM). |
In Vivo
T-1105 (Oral, 200 mg/kg, twice daily for 6 days) effectively inhibits the virus replication in the infected pigs [6] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Pigs [6] |
| Dosage: | 200 mg/kg |
| Administration: | Oral, 200 mg/kg, twice daily for 6 days |
| Result: | Reduced Viremia and increased anti-FMD antibody titers, did not observe any clinical signs of FMD. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 25 mg/mL ( 179.71 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 7.1886 mL | 35.9428 mL | 71.8856 mL |
| 5 mM | 1.4377 mL | 7.1886 mL | 14.3771 mL |
| 10 mM | 0.7189 mL | 3.5943 mL | 7.1886 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (17.97 mM); Clear solution
References
- [1] Huchting J, et al. Cell line-dependent activation and antiviral activity of T-1105, the non-fluorinated analogue of T-705 (favipiravir). Antiviral Res. 2019 Jul;167:1-5.
- [2] Furuta Y, et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009 Jun;82(3):95-102.
- [3] Johanna Huchting, et al. Cell line-dependent activation and antiviral activity of T-1105, the non-fluorinated analogue of T-705 (favipiravir). Antiviral Res. 2019 Jul;167:1-5.
- [4] Lei Cai, et al. Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replication. Arch Virol. 2017 Sep;162(9):2847-2853.
- [5] Hideki Tani, et al. Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus.
- [6] Yousuke Furuta, et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009 Jun;82(3):95-102.